Alzheimer's Disease Neuroinflammation Companies

📖 Wiki Page

company931 wordssynced 2026-04-02

Overview

flowchart TD companies_ad_neuroinflammation["Alzheimers Disease Neuroinflammation Companies"] style companies_ad_neuroinflammation fill:#4fc3f7,stroke:#333,color:#000 companies_ad_neuroin_0["Key Companies"] companies_ad_neuroinflammation -->|"includes"| companies_ad_neuroin_0 style companies_ad_neuroin_0 fill:#81c784,stroke:#333,color:#000 companies_ad_neuroin_1["NLRP3 Inflammasome Inhibitors"] companies_ad_neuroinflammation -->|"includes"| companies_ad_neuroin_1 style companies_ad_neuroin_1 fill:#ef5350,stroke:#333,color:#000 companies_ad_neuroin_2["TNF-Alpha Inhibitors"] companies_ad_neuroinflammation -->|"includes"| companies_ad_neuroin_2 style companies_ad_neuroin_2 fill:#ffd54f,stroke:#333,color:#000 companies_ad_neuroin_3["TREM2 Targeting"] companies_ad_neuroinflammation -->|"includes"| companies_ad_neuroin_3 style companies_ad_neuroin_3 fill:#ce93d8,stroke:#333,color:#000 companies_ad_neuroin_4["Complement Inhibitors"] companies_ad_neuroinflammation -->|"includes"| companies_ad_neuroin_4 style companies_ad_neuroin_4 fill:#4fc3f7,stroke:#333,color:#000 companies_ad_neuroin_5["Microglia Modulation"] companies_ad_neuroinflammation -->|"includes"| companies_ad_neuroin_5 style companies_ad_neuroin_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

This category page covers biotechnology and pharmaceutical companies developing therapies that target neuroinflammation in Alzheimer's disease. Neuroinflammation is increasingly recognized as a central driver of neurodegenerative processes, and multiple therapeutic approaches are under development targeting different aspects of the inflammatory cascade.

The main mechanisms being targeted include:

NLRP3 inflammasome inhibition
TREM2 modulation on microglia
TNF-alpha inhibition
Complement system inhibition
Microglia modulation

Key Companies

NLRP3 Inflammasome Inhibitors

Nodthera Ltd.

Focus: NLRP3 inflammasome inhibition
Lead Candidate: NT-0796
Indication: Alzheimer's disease
Stage: Phase 1/2
Mechanism: Brain-penetrant NLRP3 small molecule inhibitor
Notes: First-in-class oral therapy targeting neuroinflammation at its source[@nodthera_corp][@nlrp3_review]

Olatec Therapeutics

Focus: NLRP3 inflammasome inhibition
Lead Candidate: Dapansutrile (OLT1177)
Indication: Alzheimer's disease
Stage: Phase 2
Mechanism: Oral NLRP3 inhibitor
Notes: Established safety profile in inflammatory conditions

TNF-Alpha Inhibitors

INmune Bio, Inc.

Focus: Selective soluble TNF-alpha inhibition
Lead Candidate: XPro1595
Indication: Alzheimer's disease (MCI)
Stage: Phase 2
Mechanism: Dominant-negative inhibitor of soluble TNFα (preserves membrane-bound TNF)
Trial ID: NCT05318937
Notes: Targets neuroinflammation without compromising immune surveillance[@inmune_corp]

TREM2 Targeting

Alector, Inc.

Focus: TREM2 agonism and progranulin modulation
Lead Candidates: AL002 (TREM2 agonist), AL101 (progranulin)
Indication: Alzheimer's disease
Stage: Phase 2
Mechanism:
AL002: TREM2 agonist with Alector Brain Carrier (ABC) platform
AL101: Progranulin antibody to increase progranulin levels
Partners: Roche (AL002), GSK (AL101)
Notes: Pioneer in immuno-neurology approach, targeting microglia dysfunction[@alector_corp][@trem2_review]

Vigil Neuroscience

Focus: TREM2 agonism
Lead Candidate: VIG-100
Indication: Alzheimer's disease
Stage: Phase 1
Mechanism: TREM2 activating antibody
Notes: Focused specifically on TREM2 target[@vigil_corp]

Denali Therapeutics

Focus: TREM2 and lysosomal function
Lead Candidates: DNL919 (TREM2 agonist), DNL593 (progranulin modulator)
Indication: Alzheimer's disease, Parkinson's disease
Stage: Phase 1
Mechanism: Engineered antibodies with Brain Transport Vehicle (BTV) delivery platform
Notes: Strong foundation in lysosomal biology and neurodegenerative disease[@denali_corp]

Complement Inhibitors

Annexon Biosciences

Focus: C1q inhibition (classical complement pathway)
Lead Candidates: ANX005, ANX007
Indication: Alzheimer's disease (potential)
Stage: Phase 2 (HD), expanding to AD
Mechanism: Anti-C1q monoclonal antibody
Notes: Targets complement-mediated synaptic pruning and neuroinflammation[@annexon_corp]

Microglia Modulation

Prothelia

Focus: TREM2 and tau targeting
Lead Candidate: PRX005
Indication: Alzheimer's disease
Stage: Phase 1
Mechanism: Anti-tau antibody with microglial modulation
Notes: Targets both pathological tau and microglial function

Cassava Sciences

Focus: Neuroinflammation modulation
Lead Candidate: SavaRx
Indication: Alzheimer's disease
Stage: Phase 3
Mechanism: Novel mechanism targeting neuroinflammation
Notes: Late-stage development with potential for approval

Lundbeck

Focus: Microglial modulation
Lead Candidate: Lu AF20513
Indication: Alzheimer's disease
Stage: Phase 1
Mechanism: Amyloid/TREM2 targeting vaccine
Notes: Combination approach targeting both amyloid and microglia

Pipeline Overview

| Company | Drug | Mechanism | Phase | Indication |
|---------|------|-----------|-------|------------|
| Nodthera | NT-0796 | NLRP3 inhibitor | Phase 1/2 | AD |
| INmune Bio | XPro1595 | Anti-sTNFα | Phase 2 | AD (MCI) |
| Alector | AL002 | TREM2 agonist | Phase 2 | AD |
| Alector | AL101 | Progranulin | Phase 2 | AD |
| Vigil Neuroscience | VIG-100 | TREM2 agonist | Phase 1 | AD |
| Denali Therapeutics | DNL919 | TREM2 agonist | Phase 1 | AD |
| Annexon | ANX005 | C1q inhibitor | Phase 2 | HD→AD |
| Prothelia | PRX005 | Anti-tau/microglia | Phase 1 | AD |
| Cassava Sciences | SavaRx | Neuroinflammation | Phase 3 | AD |
| Olatec | Dapansutrile | NLRP3 inhibitor | Phase 2 | AD |

Mechanism of Action Summary

Neuroinflammation in Alzheimer's Disease

Chronic neuroinflammation in Alzheimer's disease involves multiple interconnected pathways:

Amyloid-beta deposition activates microglia

NLRP3 inflammasome assembles in activated microglia

Pro-inflammatory cytokines (IL-1β, IL-18, TNFα) are released

Tau phosphorylation is enhanced by inflammatory mediators

Synaptic dysfunction and neuronal loss result

Therapeutic Approaches

| Mechanism | Target | Companies | Development Stage |
|-----------|--------|-----------|-------------------|
| NLRP3 Inhibition | Inflammasome assembly | Nodthera, Olatec | Phase 1-2 |
| TNF-α Inhibition | Soluble TNF signaling | INmune Bio | Phase 2 |
| TREM2 Agonism | Microglial activation | Alector, Vigil, Denali | Phase 1-2 |
| Complement Inhibition | C1q-mediated pruning | Annexon | Phase 2 |
| Microglia Modulation | CSF1R, CX3CR1 | Lundbeck, Prothelia | Phase 1-3 |

Mechanism Pages

[Neuroinflammation in AD](/mechanisms/neuroinflammation-ad)
[Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
[TREM2 and Neuroinflammation](/proteins/trem2)
[NLRP3 Inflammasome](/entities/nlrp3-inflammasome)
[Complement System](/mechanisms/complement-system-neurodegeneration)
[Microglia in Neuroinflammation](/cell-types/microglia-neuroinflammation)

Investment Pages

[Neuroinflammation Therapeutics Investment Landscape](/investment/neuroinflammation-therapeutics)

Company Pages

[Nodthera Ltd.](/companies/nodthera)
[INmune Bio, Inc.](/companies/inmune-bio)
[Alector, Inc.](/companies/alector)
[Annexon Biosciences](/companies/annexon)
[Vigil Neuroscience](/companies/vigil-neuroscience)
[Denali Therapeutics](/companies/denali-therapeutics)
[AD cGAS-STING and Innate Immune Companies](/companies/ad-cgas-sting-innate-immune-companies)

Disease Pages

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)

Clinical Trial Landscape

| Company | Drug | NCT Number | Phase | Status |
|---------|------|------------|-------|--------|
| INmune Bio | XPro1595 | NCT05318937 | Phase 2 | Recruiting |
| Nodthera | NT-0796 | NCT05632433 | Phase 1/2 | Recruiting |
| Alector | AL002 | NCT05139056 | Phase 2 | Active |

References

[Nodthera Corporate Website](https://www.nodthera.com)

[INmune Bio Corporate Website](https://www.inmunebio.com)

[Alector Corporate Website](https://www.alector.com)

[Annexon Biosciences Corporate Website](https://www.annexonbio.com)

[Vigil Neuroscience Corporate Website](https://www.vigilneuroscience.com)

[Denali Therapeutics Corporate Website](https://www.denalitherapeutics.com)

[TREM2 Biology and Alzheimer's Disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38598765/)

[NLRP3 Inflammasome in Alzheimer's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37612420/)

📖 View canonical wiki page →

Alzheimer's Disease Neuroinflammation Companies

Overview

Overview

Key Companies

NLRP3 Inflammasome Inhibitors

Nodthera Ltd.

Olatec Therapeutics

TNF-Alpha Inhibitors

INmune Bio, Inc.

TREM2 Targeting

Alector, Inc.

Vigil Neuroscience

Denali Therapeutics

Complement Inhibitors

Annexon Biosciences

Microglia Modulation

Prothelia

Cassava Sciences

Lundbeck

Pipeline Overview

Mechanism of Action Summary

Neuroinflammation in Alzheimer's Disease

Therapeutic Approaches

Cross-Links to Related Pages

Mechanism Pages

Investment Pages

Company Pages

Disease Pages

Clinical Trial Landscape

See Also

References